Form 4: Avery W. Catlin Acquires Stock Options in Corbus Pharmaceuticals Holdings, Inc.

Director Avery W. Catlin acquired stock options in Corbus Pharmaceuticals Holdings, Inc. on May 16, 2024, as part of the company's 2024 Equity Compensation Plan.

Summary

• On May 16, 2024, Avery W. Catlin, a director of Corbus Pharmaceuticals Holdings, Inc., was granted stock options to purchase 2,783 shares of common stock.
• The exercise price of these options is $45.92 per share.
• The options were awarded under the issuer's 2024 Equity Compensation Plan.
• The options vest 100% on the one-year anniversary of the grant date, and expire on 05/16/2034.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of a stock option grant, which is neither particularly positive nor negative. It's a standard part of executive compensation.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment to the company.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to incentivize performance and align management interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• The size of the grant (2,783 shares) and the vesting schedule (100% after one year) appear to be fairly typical for a director-level grant, but would need to be compared to similar companies of comparable size and stage of development to determine if it is in line with industry norms.
• Companies like Madrigal Pharmaceuticals, Viking Therapeutics, and 89bio are comparible companies in the same space.

Stakeholder Impact

• The stock option grant could potentially impact shareholders by diluting ownership if the options are exercised.
• The grant incentivizes the director to work towards increasing shareholder value.

Key Dates